Drugs / BGP-014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05118919 | Feb 2022 → Dec 2024 | ulcerative colitis | BioGaia Pharma AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGP-014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118919 ↗ |
| Known as | Lactobacillus reuteri | “The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis...” NCT05118919 ↗ |
| Route | Oral | “as an oral administered local treatment” NCT05118919 ↗ |